UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

Journal of clinical oncology, 2016-01, Vol.34 (2), p.179-185

2016

Volltextzugriff (PDF)

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

Journal of clinical oncology, 2011-10, Vol.29 (28), p.3768-3774

2011

Volltextzugriff (PDF)

Phase III Evaluation of Treatment Combinations in Three-Arm Trials

Journal of clinical oncology, 2024-10

2024

Volltextzugriff (PDF)

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Journal of clinical oncology, 2014-06, Vol.32 (18), p.1927-1934

2014

Volltextzugriff (PDF)

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5124-5130

2009

Volltextzugriff (PDF)

The Master Protocol Concept

Seminars in oncology, 2015-10, Vol.42 (5), p.724-730

2015

Volltextzugriff (PDF)

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Journal of clinical oncology, 2009-04, Vol.27 (12), p.2091-2096

2009

Volltextzugriff (PDF)

Clinical Benefit Scales and Trial Design: Some Statistical Issues

JNCI : Journal of the National Cancer Institute, 2022-09, Vol.114 (9), p.1222-1227

2022

Volltextzugriff (PDF)

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Journal of clinical oncology, 2011-01, Vol.29 (1), p.11-16

2011

Volltextzugriff (PDF)

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline–directed treatment for stage II and III disease

Cancer, 2018-09, Vol.124 (17), p.3510-3519

2018

Volltextzugriff (PDF)

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

Journal of clinical oncology, 2013-01, Vol.31 (3), p.359-364

2013

Volltextzugriff (PDF)

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Journal of clinical oncology, 2012-10, Vol.30 (28), p.3499-3506

2012

Volltextzugriff (PDF)

Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?

JNCI : Journal of the National Cancer Institute, 2020-08, Vol.112 (8), p.773-778

2020

Volltextzugriff (PDF)

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

Clinical pharmacology and therapeutics, 2019-03, Vol.105 (3), p.598-613

2019

Volltextzugriff (PDF)

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

JNCI : Journal of the National Cancer Institute, 2015-11, Vol.107 (11), p.djv248

2015

Volltextzugriff (PDF)

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database

Journal of clinical oncology, 2016-03, Vol.34 (8), p.843-853

2016

Volltextzugriff (PDF)

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3385-3390

2009

Volltextzugriff (PDF)

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

European journal of cancer (1990), 2014-01, Vol.50 (2), p.320-331

2014

Volltextzugriff (PDF)

Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

Journal of clinical oncology, 2007-03, Vol.25 (7), p.767-772

2007

Volltextzugriff (PDF)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Journal of clinical oncology, 2019-10, Vol.37 (29), p.2601-2609

2019

Volltextzugriff (PDF)

Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database

JNCI : Journal of the National Cancer Institute, 2021-04, Vol.113 (4), p.400-407

2021

Volltextzugriff (PDF)

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer

JNCI : Journal of the National Cancer Institute, 2014-12, Vol.106 (12), p.1

2014

Volltextzugriff (PDF)

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials

Current colorectal cancer reports, 2015, Vol.11 (5), p.275-280

2015

Volltextzugriff (PDF)

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

PloS one, 2018-08, Vol.13 (8), p.e0200836-e0200836

2018

Volltextzugriff (PDF)

1 – 25 von 366

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(350)
Mit Volltextzugriff
(316)

Publikationsform

Sprache

Englisch
(366)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(198)
Life Sciences & Biomedicine
(194)
Humans
(185)
Oncology
(133)
Biological And Medical Sciences
(105)
Medical Sciences
(91)
Female
(66)
Male
(64)
Pharmacology. Drug Treatments
(64)
Antineoplastic Agents
(55)
Middle Aged
(52)
Adult
(43)
Aged
(40)
Tumors
(38)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(37)
Chemotherapy
(34)
Prognosis
(32)
Fluorouracil - Administration & Dosage
(31)
Pharmacology & Pharmacy
(31)
Animals
(28)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015

Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses

Phase III Evaluation of Treatment Combinations in Three-Arm Trials

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology

Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04

Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03

The Master Protocol Concept

American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

Clinical Benefit Scales and Trial Design: Some Statistical Issues

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline–directed treatment for stage II and III disease

Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database

Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial

Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials

Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations

Suchergebnisse filtern